Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.46 |
| ▸ | MELK | Q14680 | 5/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.35 |
| ▸ | GSK3B | P49841 | 2/20 | 0.34 |
| ▸ | CDK4 | P11802 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5216629 | 0.87 | PDE10A (0.44) | PDE10AMELKMKNK1GRM4DYRK1B | |
| SCHEMBL3929171 | 0.84 | GRM5 (0.49) | PDE10AMELKMKNK1GRM4 | |
| SCHEMBL30795060 | 0.84 | GRM5 (0.49) | PDE10AMELKMKNK1GRM4 | |
| SCHEMBL12203764 | 0.80 | PDE10A (0.46) | PDE10AMELKMKNK1GRM4CYP2D6 | |
| SCHEMBL5219693 | 0.79 | PDE10A (0.44) | PDE10AMELKMKNK1GRM4CYP2D6 | |
| SCHEMBL5668065 | 0.77 | GRM4 (0.48) | PDE10AMELKMKNK1GRM4 | |
| SCHEMBL5221007 | 0.76 | NPC1 (0.42) | MKNK1GRM4 | |
| SCHEMBL28245414 | 0.76 | PDE10A (0.46) | PDE10AMELKMKNK1GRM4CYP2D6 | |
| SCHEMBL14380712 | 0.74 | PDE10A (0.44) | PDE10AMELKMKNK1GRM4 | |
| SCHEMBL5218758 | 0.74 | PDE10A (0.46) | PDE10AMELKMKNK1GRM4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1458383-B1 | HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO INC (US) | 2007-11-21 | — | — | EP | claimed |
| EP-1458383-A4 | HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO INC (US) | 2005-05-25 | — | — | EP | claimed |
| US-20050026963-A1 | Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 | MERCK SHARP & DOHME LLC | 2005-02-03 | — | — | US | claimed |
| EP-1458383-A2 | HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | Merck & Co., Inc. (US) | 2004-09-22 | — | — | EP | claimed |
| WO-2004030637-A2 | TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE | MERCK & CO., INC. (US) | 2004-04-15 | — | — | WO | claimed |
| WO-2003051833-A2 | HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO., INC. (US) | 2003-06-26 | — | — | WO | claimed |
| US-7569592-B2 | Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 | MERCK & CO., INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-7569592-B2 | Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 | MERCK & CO., INC. (US) | 2009-08-04 | — | — | US | disclosed |
| WO-2003051833-A2 | HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO., INC. (US) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026963-A1 | Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 | GRM5, GRIK5, GRIN2C | PDE10A 964/4885MELK 366/4885MKNK1 893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.